Last mentioned: Apr 22, 2026
HIMS Launches GLP-1s
Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.
Settlement Reached
Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.
FDA Shortage Updates
FDA begins removing specific GLP-1 dosages from the national shortage list.
Litigation Surge
Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.
Hims & Hers Health has agreed to cease the sale of compounded GLP-1 medications as part of a legal settlement, marking a significant shift in the telehealth landscape. This move follows intense regulatory scrutiny and litigation regarding the legality of compounding patented weight-loss drugs during supply shortages.
This page surfaces every story mentioning Eli Lilly across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Eli Lilly was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |